



For Immediate Release

## OMNIA BIOLOGICS AND APARNABIO SIGN LENTIVIRUS DRUG DEVELOPMENT AGREEMENT

(August 18, 2009 – Rockville, MD) Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and drug development company Aparna Biosciences Corp. (AparnaBio) (Rockville, MD) today announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.

Omnia Biologics (Omnia) is a contract manufacturer focused on process development and clinical trials material manufacturing of innovative biopharmaceuticals. AparnaBio is developing a new class of proprietary nanomedicine drug delivery technology.

“Despite recent setbacks in lentivirus based drug development on the business side, we continue to see great promise in the platform.” Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal. “The AparnaBio team has deep experience, a level of sophistication and a track record of success that gives them a leg up on successfully executing on the commercial potential of the lentivirus drug delivery concept. We are pleased to be chosen by AparnaBio as a partner in this development effort.”

About Omnia Biologics: ([www.omniabiologics.com](http://www.omniabiologics.com))

Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

###

### CONTACT:

Omnia Biologics, Inc. 12111 Parklawn Drive, Rockville, Maryland, 20852, USA, E-mail: [info@omniabiolo.com](mailto:info@omniabiolo.com), Tel: 301-984-5928, Fax 301-984-2515.